CrossRef

IFN-α-based treatment of patients with chronic HCV show increased levels of cells with myeloid-derived suppressor cell phenotype and of IDO and NOS

Immunopharmacology and Immunotoxicology 39(4) (2017)

Mohamed Labib Salem; Abdel-Aziz A. Zidan; Mohamed Attia; Randa E. EL-Naggar; Mohamed Nassef; Abdel Raouf Abou El-Azm; Hasan El-Bate; Mohamed Yussif; Sohaila Galal; Mohamed Abo Senna; Maha El Demellawy

Untitled

Universal screening for HCV infection in China: An effectiveness and cost-effectiveness analysis

JHEP Reports 6(4) (2024)

Hua Zhou; Mengxia Yan; Datian Che; Bin Wu

Keratin 23 is a stress-inducible marker of mouse and human ductular reaction in liver disease

Journal of Hepatology 65(3) (2016)

Nurdan Guldiken; Gokce Kobazi Ensari; Pooja Lahiri; Gabrielle Couchy; Christian Preisinger; Christian Liedtke; Henning W. Zimmermann; Marianne Ziol; Peter Boor; Jessica Zucman-Rossi; Christian Trautwein; Pavel Strnad

Impact of Treatment against Hepatitis C Virus on Overall Survival of Naive Patients with Advanced Liver Disease

Antimicrobial Agents and Chemotherapy 59(2) (2015)

Blaise K. Kutala; Jeremie Guedj; Tarik Asselah; Nathalie Boyer; Feryel Mouri; Michelle Martinot-Peignoux; Dominique Valla; Patrick Marcellin; Xavier Duval

Tratamiento actual de la hepatitis C en Colombia

Hepatología (2020)

Juan Ignacio Marín-Zuluaga; Gabriel Sebastián Díaz-Ramírez

Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage: Correspondence to editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”

Clinical and Molecular Hepatology 32(1) (2026)

Teng-Yu Lee; Pei-Chien Tsai; Shou-Wu Lee; Ming-Lung Yu

Treating hepatitis C in patients with hemoglobinopathies

Expert Opinion on Orphan Drugs 3(11) (2015)

Roberta D’Ambrosio; Erika Poggiali; Maria Domenica Cappellini